LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Aktien・Rhythm Pharmaceuticals Inc

Search

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

85.77 -2.01

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

85.28

Max

91.53

Schlüsselkennzahlen
By Trading Economics
Einkommen	-8.1M -56M
Verkäufe	2.9M 60M
EPS	-0.83
Gewinnspanne	-92.559
Angestellte	414
EBITDA	-9.7M -52M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+59.18% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	4. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	126M 6B
Vorheriger Eröffnungskurs	87.78
Vorheriger Schlusskurs	85.77

Nachrichtenstimmung

By Acuity

50%

50%

154 / 344 Ranking in Healthcare

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Juni 2026, 23:36 UTC

Ergebnisse

Correction to Oracle Reports Higher 4Q Profit Article

10. Juni 2026, 23:19 UTC

Heiße Aktien

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10. Juni 2026, 23:09 UTC

Wichtige Markttreiber

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10. Juni 2026, 23:04 UTC

Ergebnisse

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10. Juni 2026, 20:44 UTC

Wichtige Markttreiber

Caterpillar Raises Quarterly Dividend 8%

10. Juni 2026, 23:49 UTC

Akquisitionen, Fusionen, Übernahmen

Elliott: Northern Star Should Take No Options Off The Table

10. Juni 2026, 23:48 UTC

Akquisitionen, Fusionen, Übernahmen

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10. Juni 2026, 23:48 UTC

Akquisitionen, Fusionen, Übernahmen

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10. Juni 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10. Juni 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10. Juni 2026, 23:46 UTC

Akquisitionen, Fusionen, Übernahmen

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10. Juni 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

10. Juni 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. Juni 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10. Juni 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10. Juni 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10. Juni 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

10. Juni 2026, 21:57 UTC

Ergebnisse

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10. Juni 2026, 21:52 UTC

Ergebnisse

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10. Juni 2026, 21:35 UTC

Ergebnisse

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10. Juni 2026, 21:22 UTC

Ergebnisse

Oracle Stock Slides on Increased Capital Spending -- WSJ

10. Juni 2026, 20:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

10. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10. Juni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. Juni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. Juni 2026, 20:39 UTC

Market Talk

Ergebnisse

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10. Juni 2026, 20:34 UTC

Ergebnisse

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10. Juni 2026, 20:33 UTC

Ergebnisse

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10. Juni 2026, 20:33 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

10. Juni 2026, 20:33 UTC

Market Talk

Ergebnisse

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

59.18% Vorteil

12-Monats-Prognose

Durchschnitt 136.77 USD 59.18%

Hoch 158 USD

Tief 105 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

14

Buy

0

Halten

0

Sell

Basierend auf 14 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Rhythm Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

154 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Andere Aktien aus dem Sektor

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat